News

Amberjack Capital Promotes Will Donnell to Managing Director

Amberjack Capital Promotes Will Donnell to Managing Director

Amberjack Capital Announces Promotion of Will Donnell

The Partners at Amberjack Capital Partners, L.P. are excited to share that Will Donnell has been promoted to Managing Director, effective immediately. This decision showcases the significant contributions Will has made to the firm since he became part of the team in 2016.

Embracing Leadership Development

Will has progressively taken on more leadership roles and has played a crucial part in the firm's successes and various initiatives. The Partners have confidence that this promotion will enable him to further apply his skills and expertise as Amberjack continues to grow.

A Proven Track Record

Before joining Amberjack, Will garnered essential experience at a boutique investment banking firm, which set a solid foundation for his success in private equity. He holds a B.A. in Business Administration and an M.S. in Finance, giving him a robust understanding of market dynamics.

About Amberjack Capital Partners

Amberjack Capital is recognized as a premier private equity firm committed to partnering with entrepreneurs and business owners. Their focus is on developing market leaders within the industrial, infrastructure, and environmental sectors. As early institutional investors in founder-led companies, Amberjack seeks high-performing businesses that are pursuing strategic goals.

Remarkable Growth and Vision

Based in Houston, Amberjack Capital has raised $2.1 billion in committed capital since 2006, investing in over 50 companies. This significant growth reflects their dedication to supporting businesses that create a meaningful impact in their respective industries.

Contact Information

If you have any inquiries, please reach out to Patrick Connelly, a Partner at Amberjack Capital. You can also contact Jason Turowsky, another Partner at the firm. Amberjack encourages discussions about potential partnerships and investment opportunities that align with their strategic focus.

Frequently Asked Questions

Who is Will Donnell?

Will Donnell has been promoted to Managing Director at Amberjack Capital, having joined the firm in 2016, and is recognized for his strong leadership skills.

What does Amberjack Capital do?

Amberjack Capital is a private equity firm dedicated to investing in and partnering with entrepreneurs, with an emphasis on building market leaders across different industries.

Where is Amberjack Capital located?

The firm is based in Houston, Texas, and has been involved in private equity since its founding in 2006.

How much capital has Amberjack raised?

Amberjack Capital has raised a total of $2.1 billion in committed capital since its establishment, showcasing its strong investment capabilities.

What sectors does Amberjack focus on?

Amberjack Capital specializes in the industrial, infrastructure, and environmental sectors, focusing on supporting high-performing companies undergoing significant changes.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lilly's Digital Healthcare Push with Hims & Hers

Updated Category News Views 194

Revolutionizing Access: Pharmaceuticals Meet Telehealth In an era where digital disruption is shaking every sector, Eli Lilly (NYSE:LLY) isn't sitting idle. They've just forged a partnership with Hims & Hers (NYSE:HIMS), one that's diving headfirst into the telehealth revolution. We're talking a slick merger of pharmaceuticals and digital platforms—offering FDA-approved...

Continue Reading
Delta Dental Expands Free Oral Care Access in NM

Updated Category News Views 160

Bridging Dental Care Gaps in New Mexico When the calendar flips to early November, Delta Dental of New Mexico is joining hands with the NM Mission of Mercy for a no-cost dental clinic at EXPO New Mexico. We're talking doors flying open at 5:15 a.m. sharp, on November 6 and 7. This isn’t some run-of-the-mill thing—they are targeting those who can't easily get or afford...

Continue Reading
Sass Magazine's 2026 COZY Issue Embraces Intentional Joy

Updated Category News Views 102

An Unexpected Shift in Sass's Seasonal Focus When you think November and December, it's easy to picture the hustle and bustle of holiday preparations—shopping, parties, running around. But toss all that hullabaloo out the window, because Sass Magazine has thrown a curveball for their 2026 release. They're steering the ship towards the calm, with their COZY Issue shaping...

Continue Reading
Lululemon Faces Class Action Amid Sales Decline

Updated Category News Views 136

Looks like Lululemon Athletica Inc. (NASDAQ: LULU) is in the hot seat, and not in the cozy yoga session kind of way. Investors are gearing up for a legal face-off thanks to a class action lawsuit alleging some serious corporate sleight of hand. What Triggered This Legal Storm? Turns out, between March 18 and September 3, 2026, things didn't go as planned for Lululemon....

Continue Reading
Tenax Sued: Investors Face Class Action Over TNX-103

Updated Category News Views 83

What Tenax Investors Need to Know Alright, folks, time to pull up a chair and pay attention to what's brewing with Tenax Therapeutics—yeah, we're talking NASDAQ: TENX. The company's head is spinning as it's caught up in a securities class action lawsuit. What's the fuss? The fine print here accuses Tenax of misleading investors about the effectiveness of their product,...

Continue Reading
TCL CSOT's OLED Move In Marks Next Phase of Growth

Updated Category News Views 96

A Landmark Moment in OLED Manufacturing Alright, let me drop a quick line here. TCL CSOT just shifted gears with their t8 production line in Guangzhou. It’s not your typical assembly line story—this one's all about pulling the future into the present. We're talking the world's first 8.6-generation Inkjet Printing OLED production line, for crying out loud. They've just...

Continue Reading
Datavault AI's Turbulent Boardroom Saga Escalates

Updated Category News Views 104

The Corporate Chess Game at Datavault AI If there's one thing Wall Street hates, it's uncertainty. And boy, does Datavault AI (NASDAQ: DVLT) deliver plenty of it right now. Founder Nathaniel Bradley has lobbed a lawsuit at the board, claiming that Chairman and CFO Brett Moyer orchestrated a coup to oust him without proper board procedures. Talk about drama fit for a soap...

Continue Reading
Koppers Navigates Q3: Margins Squeeze Amid Growth

Updated Category News Views 117

Investing in Koppers: A Mixed Bag in Q3 Well, it appears Koppers (NYSE: KOP) is doing a bit of a dance this quarter—some smooth steps, but a few stumbles in the rhythm when it comes to margins. The hardwood numbers tell an interesting tale, so let's break it down. Sales Edge Up, But Margins Suffer Koppers clocked in net sales of $499.1 million for the third quarter of...

Continue Reading
New Frontiers in Glaucoma Care: Less Drops Required?

Updated Category News Views 77

Eyeing New Glaucoma Treatment Strategies You think glaucoma treatment is all about popping eye drops day in and day out? Well, turns out, things are shifting down in Racine, Wisconsin. Folks at HelloNation have been spilling the beans on earlier glaucoma interventions that might just lighten your load of daily medications. Doctors I. Paul Singh and R. Krishna Sanka...

Continue Reading
MNTN Revenue Miss Sparks Shareholder Investigation

Updated Category News Views 79

When Revenue Goes South, Shares Follow Nothing like a Friday morning stock bloodbath to shake things up. MNTN, Inc. (NYSE:MNTN) had traders tossing back extra caffeine shots on November 5, 2026, when the company reported third-quarter revenues of $80.3 million. Let's just say that number didn't quite sit well with the folks who'd been banking on an $87.7 million...

Continue Reading

Top 5 Most Recently Viewed Articles

Perpetua Resources Corp. Class Action Lawsuit and Investor Alert

Updated Category News Views 167

Understanding the Class Action Lawsuit Against Perpetua Resources Corp. Investors in Perpetua Resources Corp. (NASDAQ: PPTA) should take note of recent developments regarding a class action securities lawsuit aimed at recovering losses incurred due to alleged securities fraud. This legal action encompasses claims made during a specific period, potentially affecting a...

Continue Reading
Telix Pharmaceuticals Hits Record Revenue and Expands Guidance

Updated Category News Views 390

Telix Pharmaceuticals Reports Record Revenues in Q3 2025 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has unveiled an impressive financial performance for the third quarter of 2025, showcasing unaudited group revenues of approximately $206 million. This figure marks a substantial year-over-year increase of 53%, revealing the company's significant growth...

Continue Reading
Bio-Techne Showcases Breakthrough Solutions at Neuroscience 2024

Updated Category News Views 208

Bio-Techne's Commitment to Neuroscience Research Bio-Techne Corporation (NASDAQ: TECH) is preparing for an exciting presentation at the Society for Neuroscience's annual meeting, Neuroscience 2024. Scheduled for October 5-9 in Chicago, this prestigious event will feature Bio-Techne as they share advancements that are setting new standards in neuroscience research....

Continue Reading
Important Update for Lineage, Inc. Investors on Class Action

Updated Category News Views 214

Class Action Suit Opportunities for Lineage, Inc. Investors The Rosen Law Firm, known for advocating investor rights, is calling attention to an essential opportunity for those who purchased common stock of Lineage, Inc. (NASDAQ: LINE). Investors should be aware of the impending lead plaintiff deadline of September 30, 2025. Why Join the Lawsuit? If you bought shares of...

Continue Reading
AST SpaceMobile Prepares for BlueBird 6 Launch and Future Growth

Updated Category News Views 129

AST SpaceMobile Gears Up for BlueBird 6 Launch AST SpaceMobile is set to launch its advanced satellite, BlueBird 6, marking a significant milestone for the company. This launch is crucial for boosting the firm’s space-based cellular broadband network and is being closely watched by investors eager to understand the company’s expansion into full-scale operations. Key...

Continue Reading